(Sharecast News) - Sexual health specialist Futura Medical announced the successful acquisition of an EU patent for its MED3000 topical erectile dysfunction product on Monday.
The AIM-traded firm said the patent would ensure protection for MED3000 across all European markets until 2040.
In addition to its European victory, Futura Medical said it was actively pursuing patent applications in other significant erectile dysfunction (ED) markets, including the United States.
The company was also exploring further patent filings that could extend the scope of its protection for MED3000.
"The allowance of this patent application further cements the intellectual property of MED3000, as we support our distributors' roll out of our fast-acting topically applied gel for the treatment of erectile dysfunction available without a doctor's prescription across the world," said chief executive officer James Barder.
"This is an important next step as we continue to grow our business and strengthen the Eroxon brand."
At 1440 BST, shares in Futura Medical were up 3.68% at 44.06p.
Reporting by Josh White for Sharecast.com.
Futura Medical (FUM)